Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first‐line palliative chemotherapy
Inkeun Park(Asan Medical Center), Myung‐Hwan Kim(Korea Aerospace Research Institute), Sung Koo Lee(Ulsan College), Dong Wan Seo(Dankook University), Jae‐Lyun Lee(Ulsan College), Min‐Hee Ryu(Ulsan College), Sang Soo Lee(Chungbuk National University Hospital), Tae‐Won Kim(The Catholic University of Korea Incheon St. Mary's Hospital), Sung Sook Lee(Inje University Haeundae Paik Hospital), Do Hyun Park(Massachusetts Institute of Technology)
Cited by 75
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
TIMP-2 Mediated Inhibition of Angiogenesis
|Cell|2003|510